Supriya Lifescience Ltd - 543434 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivani Satish Wagh
Supriya Lifescience Aims To Double Revenue To Rs 1,000 Crore By FY27 Know Your Company
The manufacturer of active pharmaceutical ingredients is also planning a capex of Rs 100 crore in the next two-three years. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find the attachment. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find the attachment.
Supriya Lifescience Q3 Review - Strong Growth Across Board On Favorable Geographical, Product Mix: DRChoksey
Expansion into a more regulated market boosts the top-line Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find the attachment. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Please find the attachment. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attachment. Supriya Lifescience Ltd - 543434 - Audio Recording Of Earnings Call
Please find attachment.